MRI测定的肝脏脂肪含量变化不能预测治疗诱导的脂肪性肝炎组织学改善
本研究纳入121例曾参加吡格列酮随机对照试验的NASH患者,分析磁共振波谱测定的肝内甘油三酯(IHTG)变化与肝组织学变化的关系。结果显示IHTG变化与组织学脂肪变相关(r=0.54,p<0.01),但IHTG下降幅度与主要组织学终点应答率、NASH消退、小叶炎症、肝细胞气球样变或纤维化变化均无关,提示IHTG应答需谨慎解读。
要点
- IHTG变化与组织学脂肪变相关,但不能预测NASH组织学改善。
- IHTG下降幅度与NAFLD活动度评分2分改善或NASH消退无关。
- 以MRI肝脂肪变化评估NASH疗效需谨慎,可能不可靠。
核心结论
- IHTG变化可预测脂肪变变化,但不预测其他肝脏组织学参数变化。
- IHTG对治疗的反应应谨慎解读,可能不如既往认为的那样可靠地预测NASH患者的整体临床疗效。
研究设计与样本
- 纳入曾参加吡格列酮随机对照试验、具有完整配对磁共振波谱IHTG数据和肝组织学数据的NASH患者,共121例。
主要发现
- IHTG变化与组织学脂肪变相关(r=0.54;p<0.01)。
- IHTG下降幅度与主要组织学结局应答率无关,该结局定义为NAFLD活动度评分中2个不同参数改善2分且纤维化未恶化。
- IHTG下降幅度与NASH消退且纤维化未恶化无关,在吡格列酮组和安慰剂组均如此。
- 小叶炎症、肝细胞气球样变或肝纤维化的变化与IHTG变化无关, irrespective of treatment arm。
- 脂肪变消退与更好的组织学结局无关。
关键数值与推荐
- IHTG变化按连续变量(相关性)、分类分组(IHTG变化≥0%;或IHTG减少1-30%、31-50%、51-70%或>70%)及二分类(脂肪变消退与否,定义为达到IHTG<5.56%)评估。
- 主要组织学结局应答定义为NAFLD活动度评分中2个不同参数改善2分且纤维化未恶化。
临床怎么用
- 在NASH治疗评估中,不应仅依赖MRI测定的IHTG变化来推断组织学改善。
- IHTG下降幅度不能替代肝组织学来判定NASH治疗的整体疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Proof-of-concept studies frequently assess changes in intrahepatic triglyceride (IHTG) content by magnetic resonance-based techniques as a surrogate marker of histology. The aim of this study was to establish how reliable this strategy is to predict changes in liver histology in patients with non-alcoholic steatohepatitis (NASH). METHODS: Patients with NASH who had participated in our prior randomized controlled trials of pioglitazone with complete paired data for IHTG content by magnetic resonance spectroscopy and liver histology were included in the study. RESULTS: A total of 121 patients were included. Changes in IHTG were assessed in several ways: as a continuous variable (correlations), as categorical groups (IHTG change ≥0%; or IHTG reduction of 1-30%; 31-50%; 51-70%; or >70%), and in a binomial way as steatosis resolution or not (defined as achieving IHTG <5.56%). Changes in IHTG correlated with steatosis on histology (r = 0.54; p <0.01). However, the magnitude of IHTG reduction was not associated with the rate of response of the primary histological outcome (2-point improvement in the NAFLD activity score from 2 different parameters, without worsening of fibrosis) or resolution of NASH without worsening of fibrosis, neither in patients receiving pioglitazone nor placebo. Changes in lobular inflammation, hepatocyte ballooning, or liver fibrosis were also independent of changes in IHTG, irrespective of treatment arm. Steatosis resolution was not associated with better histological outcomes either. CONCLUSIONS: Changes in IHTG predict changes in steatosis but not of other liver histological parameters. This implies that IHTG response to treatment should be interpreted with caution, as it may not be as reliable as previously believed to predict a treatment's overall clinical efficacy in patients with NASH. LAY SUMMARY: Quantification of liver fat by magnetic resonance imaging (MRI) is currently used to assess treatment responses in patients with fatty liver, with the assumption that improvements in liver fat translate into less inflammation, necrosis, and fibrosis in the liver. However, in this article, we showed that changes in liver fat do not necessarily translate into changes in these parameters. This means that MRI may not be as useful to assess treatment response in patients with fatty liver as previously believed.
引用
- Bril F, Barb D, Lomonaco R, et al. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. J Hepatol. 2019. PMID: 31589891. doi:10.1016/j.jhep.2019.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。